Multiple Sclerosis - Pipeline Review, H1 2016; New Report Launched
Multiple Sclerosis pipeline therapeutics constitutes close to 323 molecules. Out of which approximately 279 molecules are developed by Companies and remaining by the Universities/Institutes. Global Markets Direct's latest report Multiple Sclerosis – Pipeline Review, H1 2016, outlays comprehensive information on the therapeutics under development for Multiple Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
View full press release